Hims & Hers Health (NYSE:HIMS) Given New $31.00 Price Target at Needham & Company LLC

Hims & Hers Health (NYSE:HIMS) had its price target increased by Needham & Company LLC from $28.00 to $31.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 16.41% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $23.86.

Hims & Hers Health Stock Up 5.7 %

Shares of HIMS stock opened at $26.63 on Monday. Hims & Hers Health has a 12 month low of $8.09 and a 12 month high of $35.02. The firm has a market cap of $5.82 billion, a PE ratio of 60.52 and a beta of 1.25. The stock has a 50 day moving average of $26.66 and a 200-day moving average of $21.50.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, equities analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 4,213 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the transaction, the chief financial officer now owns 128,365 shares in the company, valued at approximately $3,848,382.70. This represents a 3.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total value of $483,964.91. Following the transaction, the insider now owns 193,601 shares of the company’s stock, valued at approximately $5,415,019.97. The trade was a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,064,514 shares of company stock valued at $26,712,334. 17.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Main Management ETF Advisors LLC acquired a new position in Hims & Hers Health during the third quarter worth $672,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth about $604,000. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $5,531,000. Royce & Associates LP increased its position in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Finally, Versor Investments LP bought a new stake in Hims & Hers Health during the third quarter worth about $634,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.